Page 66 - Revista SPORL - Vol 45. Nº2
P. 66
HENRIQUES PEREIRA, RICARDO; CARDOSO; EDUARDO; SANTOS, MARGARIDA
mumu: »on:
the pathogenesis of pemphigus. Autoim-
munin. Nov; 39(7): 541-7. 2006
1 Anhalt GJ, Díaz LA. Research advances
Gorshfein A; Shoenfeld Y. The mosaic oÍ
in pemphigus. JAMA, 285(5): pemphigus. Harefuah Nov; 140(1 1):
652-54. 2001 1049-53. 2001
Caballero C G, Reyes V J. Pênfigo. Med Hameed, A; Khan, A. A. Microscopic
Oral; 4: 119-21. 2000 Nikolsky's sign. Clin Exp Dermatol.
Calebotto, A.; Soenz, A.M.; González, England.Ju1,. 24 (4) p. 312-4. 1999
F.; Carvalho, M.; Castillo, R. Pemphigus Korman NJ. New and emerging therapies
vulgaris: benefits of tetracycline as adju- in the treatment of blistering diseases.
vant therapy in a series of thirteen patien- Dermatology Clinics; 18: 127-37. 2000
ts. Int. J Dermatol. USA. Mar,. 38 (3). p. 10 Regezzi, J y Sciubba, J. Patologia Bucal.
217-21. 1999 3° edición. Edit. Inieramericono.
Chan W. Adiuvant therapies of pemphi- México,. p. 13-19. 2000
gus vulgaris: a review. Hong Kong Der- 11 Sopp JP; Eversole LE; Wysocki GP. Poro-
motol & Venereol Bull March; 10(1): logia Moxilofociol Contemporânea. Edit.
4-9. 2002 Harcourt Brace. Espafio, 256-59. 1998
Dick SE, Worth VP. Pemphígus: A treat- 12 Sirois D; leigh JE; Sollecito TP. Oral pem-
ment update. Autoimmunity. Nov; 39(7): phigus vulgaris preceding cutaneous le-
591-9. 2006 sions: recognition and diagnosis. J Am
Gniadecki R. Desmoglein autoimmunity in DentAssoc Aug; 131(8): 1156-60. 2000
I76
